Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
What is the ticker symbol for Minerva Neurosciences Inc? What does NERV stand for in stocks?
NERV is the stock ticker symbol of Minerva Neurosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Minerva Neurosciences Inc (NERV)?
As of Fri Dec 20 2024, market cap of Minerva Neurosciences Inc is 15.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of NERV stock?
You can check NERV's fair value in chart for subscribers.
Is Minerva Neurosciences Inc a good stock to buy?
The fair value guage provides a quick view whether NERV is over valued or under valued. Whether Minerva Neurosciences Inc is cheap or expensive depends on the assumptions which impact Minerva Neurosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NERV.
What is 5 year return on Minerva Neurosciences Inc's stock?
In the past 10 years, Minerva Neurosciences Inc has provided -0.26 (multiply by 100 for percentage) rate of return.